Regional Bacillus Calmette-Guérin lymphadenitis after initiating antiretroviral therapy in an infant with human immunodeficiency virus type 1 infection.
Sharp
M J
MJ
Department of Immunology, Princess Margaret Hospital, Subiaco, Western Australia.
Mallon
D F
DF
D019380:Anti-HIV Agents / Q000627:therapeutic use*; D001500:BCG Vaccine / Q000009:adverse effects*; D015658:HIV Infections / Q000151:congenital / Q000188:drug therapy*; D015497:HIV-1; D006801:Humans; D016867:Immunocompromised Host; D007223:Infant; D008199:Lymphadenitis / Q000209:etiology / Q000382:microbiology*; D008297:Male; D009163:Mycobacterium bovis / Q000302:isolation & purification*
D019380:Anti-HIV Agents; D001500:BCG Vaccine